97 related articles for article (PubMed ID: 8282820)
41. Single nucleotide polymorphisms linked to mitochondrial uncoupling protein genes UCP2 and UCP3 affect mitochondrial metabolism and healthy aging in female nonagenarians.
Kim S; Myers L; Ravussin E; Cherry KE; Jazwinski SM
Biogerontology; 2016 Aug; 17(4):725-36. PubMed ID: 26965008
[TBL] [Abstract][Full Text] [Related]
42. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
[TBL] [Abstract][Full Text] [Related]
43. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
[TBL] [Abstract][Full Text] [Related]
44. Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression.
Scholl FA; Betts DR; Niggli FK; Schäfer BW
Br J Cancer; 2000 Mar; 82(6):1239-45. PubMed ID: 10735512
[TBL] [Abstract][Full Text] [Related]
45. Rhabdomyosarcomas do not contain mutations in the DNA binding domains of myogenic transcription factors.
Anand G; Shapiro DN; Dickman PS; Prochownik EV
J Clin Invest; 1994 Jan; 93(1):5-9. PubMed ID: 8282820
[TBL] [Abstract][Full Text] [Related]
46. Failure of Myf5 to support myogenic differentiation without myogenin, MyoD, and MRF4.
Valdez MR; Richardson JA; Klein WH; Olson EN
Dev Biol; 2000 Mar; 219(2):287-98. PubMed ID: 10694423
[TBL] [Abstract][Full Text] [Related]
47. Myogenin's functions do not overlap with those of MyoD or Myf-5 during mouse embryogenesis.
Rawls A; Morris JH; Rudnicki M; Braun T; Arnold HH; Klein WH; Olson EN
Dev Biol; 1995 Nov; 172(1):37-50. PubMed ID: 7589813
[TBL] [Abstract][Full Text] [Related]
48. A point mutation in the MyoD basic domain imparts c-Myc-like properties.
Van Antwerp ME; Chen DG; Chang C; Prochownik EV
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9010-4. PubMed ID: 1329087
[TBL] [Abstract][Full Text] [Related]
49. Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin.
Wang Y; Schnegelsberg PN; Dausman J; Jaenisch R
Nature; 1996 Feb; 379(6568):823-5. PubMed ID: 8587605
[TBL] [Abstract][Full Text] [Related]
50. Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells.
Ma H; Urquidi V; Wong J; Kleeman J; Goodison S
Mol Cancer Res; 2003 Aug; 1(10):739-46. PubMed ID: 12939399
[TBL] [Abstract][Full Text] [Related]
51. Rhabdomyosarcoma: clinical and pathological features and comparison with human fetal and embryonal skeletal muscle.
PATTON RB; HORN RC
Surgery; 1962 Oct; 52():572-84. PubMed ID: 14484432
[No Abstract] [Full Text] [Related]
52. Differential patterns of DNA binding by myc and max proteins.
Prochownik EV; VanAntwerp ME
Proc Natl Acad Sci U S A; 1993 Feb; 90(3):960-4. PubMed ID: 8430110
[TBL] [Abstract][Full Text] [Related]
53. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.
Zervos AS; Gyuris J; Brent R
Cell; 1993 Jan; 72(2):223-32. PubMed ID: 8425219
[TBL] [Abstract][Full Text] [Related]
54. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.
Ayer DE; Kretzner L; Eisenman RN
Cell; 1993 Jan; 72(2):211-22. PubMed ID: 8425218
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
